MX2018002738A - Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4. - Google Patents
Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4.Info
- Publication number
- MX2018002738A MX2018002738A MX2018002738A MX2018002738A MX2018002738A MX 2018002738 A MX2018002738 A MX 2018002738A MX 2018002738 A MX2018002738 A MX 2018002738A MX 2018002738 A MX2018002738 A MX 2018002738A MX 2018002738 A MX2018002738 A MX 2018002738A
- Authority
- MX
- Mexico
- Prior art keywords
- present description
- derivatives
- medicaments
- compounds
- tricyclic fused
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- -1 complexes Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción describe compuestos heterocíclicos de fórmula I: (ver Fórmula) o sus estereoisómeros, sales farmacéuticamente aceptables, complejos, hidratos, solvatos, tautómeros, polimorfos, mezclas racémicas, formas ópticamente activas y derivados farmacéuticamente activos del mismo y composiciones farmacéuticas que los contienen como el ingrediente activo; la presente descripción describe también la síntesis y caracterización de los compuestos mencionados anteriormente que exhiben alta actividad anti-cáncer; los compuestos de la presente descripción son útiles como medicamentos y su uso en la fabricación de medicamentos para el tratamiento, prevención o supresión de enfermedades y condiciones mediadas por uno o más bromodominios de la familia BET.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4781CH2015 | 2015-09-09 | ||
| PCT/IN2016/050300 WO2017042834A1 (en) | 2015-09-09 | 2016-09-08 | Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018002738A true MX2018002738A (es) | 2018-04-13 |
| MX382128B MX382128B (es) | 2025-03-11 |
Family
ID=57346000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018002738A MX382128B (es) | 2015-09-09 | 2016-09-08 | Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10689395B2 (es) |
| EP (1) | EP3347356B1 (es) |
| JP (1) | JP6838052B2 (es) |
| KR (1) | KR102759651B1 (es) |
| CN (1) | CN108137588B (es) |
| AU (1) | AU2016319638B2 (es) |
| CA (1) | CA2997531A1 (es) |
| CY (1) | CY1124245T1 (es) |
| DK (1) | DK3347356T3 (es) |
| ES (1) | ES2866073T3 (es) |
| HR (1) | HRP20210581T1 (es) |
| HU (1) | HUE053912T2 (es) |
| IL (1) | IL257473B (es) |
| LT (1) | LT3347356T (es) |
| MX (1) | MX382128B (es) |
| PL (1) | PL3347356T3 (es) |
| PT (1) | PT3347356T (es) |
| RS (1) | RS61803B1 (es) |
| RU (1) | RU2734959C2 (es) |
| SI (1) | SI3347356T1 (es) |
| SM (1) | SMT202100277T1 (es) |
| WO (1) | WO2017042834A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106029653A (zh) | 2014-01-31 | 2016-10-12 | 达纳-法伯癌症研究所股份有限公司 | 二氨基嘧啶苯砜衍生物及其用途 |
| WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| RU2750164C2 (ru) | 2015-09-11 | 2021-06-22 | Дана-Фарбер Кэнсер Инститьют, Инк. | Цианотиенотриазолодиазепины и пути их применения |
| PE20181086A1 (es) | 2015-09-11 | 2018-07-05 | Dana Farber Cancer Inst Inc | Acetamida tienotrizolodiazepinas y usos de las mismas |
| MX2018006499A (es) | 2015-11-25 | 2018-08-01 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos. |
| WO2018086605A1 (zh) * | 2016-11-10 | 2018-05-17 | 山东罗欣药业集团股份有限公司 | 一种含氮大环类化合物、其制备方法、药物组合物及应用 |
| WO2020011086A1 (zh) * | 2018-07-13 | 2020-01-16 | 四川科伦博泰生物医药股份有限公司 | 苯并二氮杂环类化合物、其制备方法及用途 |
| CN119841849B (zh) * | 2024-09-26 | 2025-08-15 | 浙江大学 | 一种吡啶酮类化合物、合成方法及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2008133288A1 (ja) | 2007-04-25 | 2010-07-29 | 第一三共株式会社 | 三環性アリール化合物 |
| PE20140918A1 (es) | 2009-09-28 | 2014-08-06 | Hoffmann La Roche | Compuestos de benzoxepina inhibidores de la pi3k |
| AR084070A1 (es) * | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| AR095266A1 (es) * | 2013-03-12 | 2015-09-30 | Abbvie Inc | Inhibidores de bromodominios tetraciclicos |
| ES2911886T3 (es) | 2015-03-30 | 2022-05-23 | Jubilant Biosys Ltd | Derivados condensados tricíclicos de 1-(ciclo)alquilpiridin-2-ona útiles para el tratamiento del cáncer |
-
2016
- 2016-09-08 RU RU2018112015A patent/RU2734959C2/ru active
- 2016-09-08 PL PL16798006T patent/PL3347356T3/pl unknown
- 2016-09-08 WO PCT/IN2016/050300 patent/WO2017042834A1/en not_active Ceased
- 2016-09-08 RS RS20210541A patent/RS61803B1/sr unknown
- 2016-09-08 PT PT167980069T patent/PT3347356T/pt unknown
- 2016-09-08 SM SM20210277T patent/SMT202100277T1/it unknown
- 2016-09-08 CA CA2997531A patent/CA2997531A1/en active Pending
- 2016-09-08 AU AU2016319638A patent/AU2016319638B2/en active Active
- 2016-09-08 MX MX2018002738A patent/MX382128B/es unknown
- 2016-09-08 EP EP16798006.9A patent/EP3347356B1/en active Active
- 2016-09-08 DK DK16798006.9T patent/DK3347356T3/da active
- 2016-09-08 LT LTEP16798006.9T patent/LT3347356T/lt unknown
- 2016-09-08 HR HRP20210581TT patent/HRP20210581T1/hr unknown
- 2016-09-08 US US15/754,292 patent/US10689395B2/en active Active
- 2016-09-08 KR KR1020187009754A patent/KR102759651B1/ko active Active
- 2016-09-08 JP JP2018511681A patent/JP6838052B2/ja active Active
- 2016-09-08 SI SI201631188T patent/SI3347356T1/sl unknown
- 2016-09-08 ES ES16798006T patent/ES2866073T3/es active Active
- 2016-09-08 HU HUE16798006A patent/HUE053912T2/hu unknown
- 2016-09-08 CN CN201680060520.9A patent/CN108137588B/zh active Active
-
2018
- 2018-02-12 IL IL257473A patent/IL257473B/en unknown
-
2020
- 2020-05-11 US US16/872,309 patent/US11267820B2/en active Active
-
2021
- 2021-05-07 CY CY20211100393T patent/CY1124245T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018002738A (es) | Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4. | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2019010354A (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| MX2020012520A (es) | Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia. | |
| UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
| MX2018003432A (es) | Compuestos heterociclicos y usos de los mismos. | |
| MX2016009013A (es) | Derivados de heterociclilo biciclicos como inhibores de cinasa-4 asociada al receptor de interleucina-1 (irak4). | |
| UY36112A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| MX2017016344A (es) | Compuestos de benzoxacepina oxazolidinona y metodos de uso. | |
| MX374729B (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4. | |
| PH12016501355A1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
| BR112016016844A2 (pt) | Compostos heterocíclicos | |
| UY35972A (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| MX2017000183A (es) | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. | |
| SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
| UY36124A (es) | Derivados de carboxamida | |
| CL2018000783A1 (es) | Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| DOP2015000214A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| MX2017012387A (es) | Derivados fusionados triciclicos de 1-(ciclo)alquil piridin-2-ona utiles para el tratamiento de cancer. | |
| MX2020003832A (es) | Compuestos heteroarilos como moduladores alostericos positivos del receptor muscarinico m1. | |
| ECSP18056196A (es) | Derivados de indano |